Company will share findings from its recent scientific study into cross contamination
July 6, 2010ALBUQUERQUE, N.M. – An expert in product containment at OSO BioPharmaceuticals Manufacturing LLC will speak at two upcoming international conferences presenting an improved scientific approach to managing the risk of cross contamination.
Kimberly K. Ray, a senior project manager at OsoBio, will serve as a featured speaker at conferences organized by ISPE, the International Society for Pharmaceutical Engineering. With more than 25,000 members in 90 countries, ISPE is the world’s largest not–for–profit association dedicated to educating pharmaceutical manufacturing professionals and advancing their industry.
Ray will speak at the ISPE Brussels Conference being held Sept. 20–23 in Brussels, Belgium, and again at the ISPE Risk–MaPP Conference in Washington, D.C., from Oct. 4–5.
The holder of a Lean Six Sigma black belt in practices designed to improve manufacturing processes and eliminate defects, Ray will discuss findings from a scientific study OsoBio recently conducted examining cross contamination. OsoBio documented that its internal quality assurance procedures are safe and effective in containing live viruses and other potentially hazardous compounds.
“There is a mindset within the pharmaceutical industry that potent compounds must be handled in separate, dedicated facilities,” said David Pittman, director of technical operations. “What we’ve done is provide scientific evidence that a multi–product–line facility like OsoBio can safely and effectively contain hard–to–handle compounds.”
Headquartered in Albuquerque, OsoBio is a contract manufacturing and drug development organization for sterile and injectable biologic and pharmaceutical products. The company specializes in sterile injectables that require complex handling.
Known for its attention to detail and customer service, OsoBio employees are industry veterans who provide innovative solutions to difficult projects.